Microdosing isn’t just popular for psychedelics. Some consumers are taking smaller than standard doses of GLP-1s—the popular ...

According to the Market Research Blog, "the total U.S. weight loss market is estimated to have grown to a historic peak of ...

Should Medicare and Medicaid eventually cover new weight loss drugs such as Ozempic and Wegovy? This week, Audacy took a look ...

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more ...

Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests Illustration of a semaglutide peptide (blue) bound to its target glucagon-like peptide-1 (GLP-1, light pink).

The data showed patients who took GLP-1 drugs had a much lower risk of developing cancer than those who took DDP-4s.